U.S. clinical-stage biotech Viridian Therapeutics is shoring up its commercial supply infrastructure as its thyroid eye disease (TED) candidate, veligrotug, approaches a critical regulatory milestone with a U.S. FDA approval decision expected next month. Ahead of the prospective product launch, the Waltham, Massachusetts-based developer has formalized a long-term supply agreement with Chinese contract manufacturing giant WuXi Biologics. According to a regulatory filing with the U.S. Securities and Exchange Commission (SEC) dated May 26, WuXi Biologics is contracted to supply both drug substance and finished drug product for commercial utilization over an initial 5-year timeline, with subsequent extension configurations available.
The primary contractual frameworks, geopolitical risk clauses, and market valuation tracking metrics include:
-
Non-Exclusive Supply Architecture: Viridian stipulated within the regulatory filing that WuXi Biologics will operate as a “non-exclusive supplier”. This structural flexibility enables the biotech firm to freely engage alternative contract development and manufacturing organizations (CDMOs) to diversify its sourcing channels for veligrotug.
-
Geopolitical and Legislative Escape Clauses: The supply pact incorporates an early termination clause that can be triggered if changes in applicable statutory laws materially and adversely compromise WuXi Biologics’ operational capacity to execute its services. This provision materializes amidst ongoing political rhetoric in Washington aimed at curbing China’s expanding biopharma footprint, illustrated by policy debates surrounding the Biosecure Act and the proposed COINS Act. Notably, near-term pressures on WuXi Biologics subsided after the corporation’s name was omitted from the definitive final text of the Biosecure legislation.
-
Volume-Based Pricing and Binding Forecasts: Under the terms of the agreement, Viridian is mandated to furnish its CDMO partner with rolling product volume requirements, a designated percentage of which will be locked in as a binding and non-cancellable financial commitment. The commercial layout features volume-dependent pricing models for the veligrotug supply chain, supplemented by specialized service fees and ancillary processing costs, though specific fiscal breakdowns were withheld.
-
Pivotal Regulatory Deadline and Competitive Landscape: Backed by a series of positive Phase III clinical trial readouts, Viridian is managing toward a critical June 30 FDA Prescription Drug User Fee Act (PDUFA) action date. Upon potential marketing clearance, the novel biologic is set to enter direct commercial competition with Amgen’s entrenched blockbuster therapy, Tepezza, which captured $1.9 billion in worldwide sales last year.
Despite macroeconomic friction, WuXi Biologics’ global tracking metrics show a robust volume of new project bookings heavily supported by U.S. biopharma clients. Prior to the Viridian transaction, the manufacturer secured a significant production contract in February with Vertex Pharmaceuticals to manufacture the latter’s trispecific T-cell engager candidate developed for B-cell mediated autoimmune disorders.